Please select the option that best describes you:
Topics:
Breast Cancer • Head and Neck Cancers • Genitourinary Cancers • Thoracic Malignancies • Bladder Cancer • Medical Oncology • Renal Cell Carcinoma • Non-small cell lung cancer
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
For instance, the pembrolizumab approval only looked at NSCLC patients. Do you extrapolate noninferiority to all indications for pembrolizumab, nivolumab, and/or atezolizumab?